Kiora Book Value Per Share from 2010 to 2024

KPRX Stock

USD 3.31 0.11 3.22%

Kiora Pharmaceuticals Book Value Per Share yearly trend continues to be fairly stable with very little volatility. Book Value Per Share is likely to outpace its year average in 2024. Book Value Per Share is the ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of Kiora Pharmaceuticals according to its financial statements. View All Fundamentals

Book Value Per Share

First Reported

2010-12-31

Previous Quarter

11.35608644

Current Value

11.92

Quarterly Volatility

2 K

Credit Downgrade

Yuan Drop

Covid

Check Kiora Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Kiora Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 84.2 K, Selling General Administrative of 4.8 M or Other Operating Expenses of 10.3 M, as well as many indicators such as Price To Sales Ratio of 16 K, Dividend Yield of 0.0 or PTB Ratio of 0.43. Kiora financial statements analysis is a perfect complement when working with Kiora Pharmaceuticals Valuation or Volatility modules.

Check out the analysis of Kiora Pharmaceuticals Correlation against competitors.

For more information on how to buy Kiora Stock please use our How to Invest in Kiora Pharmaceuticals guide.

Latest Kiora Pharmaceuticals' Book Value Per Share Growth Pattern

Below is the plot of the Book Value Per Share of Kiora Pharmaceuticals over the last few years. It is the ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of a company according to its financial statements. Kiora Pharmaceuticals' Book Value Per Share historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Kiora Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 7.14 X

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Book Value Per Share

Timeline

Kiora Book Value Per Share Regression Statistics

	Arithmetic Mean	(1,244)
	Coefficient Of Variation	(157.53)
	Mean Deviation	1,773
	Median	11.36
	Standard Deviation	1,959
	Sample Variance	3.8M
	Range	4.9K
	R-Value	0.80
	Mean Square Error	1.5M
	R-Squared	0.64
	Significance	0.0004
	Slope	349.34
	Total Sum of Squares	53.7M

Kiora Book Value Per Share History

	2024	11.92
	2023	11.36
	2022	15.58
	2021	38.26
	2020	60.98
	2019	83.28
	2018	151.11

Other Fundumenentals of Kiora Pharmaceuticals

Tangible Book Value Per Share

Kiora Pharmaceuticals Book Value Per Share component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Current Deferred Revenue	Good Will	Intangible Assets	Net Tangible Assets	Deferred Long Term Liab	Net Invested Capital	Net Working Capital	Property Plant Equipment	Capital Stock	Long Term Debt	Short Long Term Debt
Total Assets		0.93	-0.68	-0.82	0.31	0.43	-0.87	0.76	-0.48	0.49	0.47	-0.73	0.61	0.74	0.67	0.79	0.77	0.52	-0.66	-0.17	-0.17
Total Stockholder Equity	0.93		-0.69	-0.79	0.3	0.47	-0.99	0.76	-0.55	0.51	0.42	-0.69	0.43	0.7	0.53	0.73	0.71	0.43	-0.63	-0.26	-0.26
Net Debt	-0.68	-0.69		0.31	-0.15	-0.14	0.69	-0.95	0.67	-0.61	-0.45	0.31	-0.03	-0.28	-0.06	-0.34	-0.38	-0.16	0.07	-0.11	-0.11
Retained Earnings	-0.82	-0.79	0.31		-0.11	-0.77	0.7	-0.48	0.32	-0.26	-0.34	0.91	-0.7	-0.92	-0.78	-0.83	-0.83	-0.82	0.84	0.64	0.64
Accounts Payable	0.31	0.3	-0.15	-0.11		0.01	-0.29	0.18	-0.02	-0.05	0.37	0.11	0.21	-0.13	0.05	-0.06	-0.15	0.0	-0.02	0.18	0.18
Net Receivables	0.43	0.47	-0.14	-0.77	0.01		-0.41	0.35	-0.22	-0.03	0.09	-0.67	0.61	0.69	0.61	0.47	0.47	0.88	-0.57	-0.81	-0.81
Total Liab	-0.87	-0.99	0.69	0.7	-0.29	-0.41		-0.74	0.55	-0.5	-0.35	0.63	-0.34	-0.64	-0.46	-0.67	-0.66	-0.32	0.58	0.19	0.19
Total Current Assets	0.76	0.76	-0.95	-0.48	0.18	0.35	-0.74		-0.53	0.61	0.48	-0.46	0.16	0.44	0.18	0.44	0.49	0.36	-0.19	-0.07	-0.07
Short Term Debt	-0.48	-0.55	0.67	0.32	-0.02	-0.22	0.55	-0.53		-0.3	-0.29	0.28	-0.13	-0.29	-0.18	-0.29	-0.29	-0.16	0.24	0.14	0.14
Common Stock	0.49	0.51	-0.61	-0.26	-0.05	-0.03	-0.5	0.61	-0.3		0.37	-0.3	-0.2	0.34	-0.05	0.37	0.41	-0.01	0.11	-0.04	-0.04
Current Deferred Revenue	0.47	0.42	-0.45	-0.34	0.37	0.09	-0.35	0.48	-0.29	0.37		-0.05	0.02	0.06	0.02	0.02	0.02	0.1	-0.03	-0.17	-0.17
Good Will	-0.73	-0.69	0.31	0.91	0.11	-0.67	0.63	-0.46	0.28	-0.3	-0.05		-0.59	-0.99	-0.71	-0.93	-0.96	-0.79	0.83	0.51	0.51
Intangible Assets	0.61	0.43	-0.03	-0.7	0.21	0.61	-0.34	0.16	-0.13	-0.2	0.02	-0.59		0.61	0.94	0.62	0.53	0.72	-0.74	-0.31	-0.31
Net Tangible Assets	0.74	0.7	-0.28	-0.92	-0.13	0.69	-0.64	0.44	-0.29	0.34	0.06	-0.99	0.61		0.74	0.94	0.96	0.78	-0.82	-0.56	-0.56
Deferred Long Term Liab	0.67	0.53	-0.06	-0.78	0.05	0.61	-0.46	0.18	-0.18	-0.05	0.02	-0.71	0.94	0.74		0.71	0.67	0.71	-0.81	-0.35	-0.35
Net Invested Capital	0.79	0.73	-0.34	-0.83	-0.06	0.47	-0.67	0.44	-0.29	0.37	0.02	-0.93	0.62	0.94	0.71		0.97	0.59	-0.83	-0.3	-0.3
Net Working Capital	0.77	0.71	-0.38	-0.83	-0.15	0.47	-0.66	0.49	-0.29	0.41	0.02	-0.96	0.53	0.96	0.67	0.97		0.63	-0.79	-0.32	-0.32
Property Plant Equipment	0.52	0.43	-0.16	-0.82	0.0	0.88	-0.32	0.36	-0.16	-0.01	0.1	-0.79	0.72	0.78	0.71	0.59	0.63		-0.62	-0.69	-0.69
Capital Stock	-0.66	-0.63	0.07	0.84	-0.02	-0.57	0.58	-0.19	0.24	0.11	-0.03	0.83	-0.74	-0.82	-0.81	-0.83	-0.79	-0.62		0.4	0.4
Long Term Debt	-0.17	-0.26	-0.11	0.64	0.18	-0.81	0.19	-0.07	0.14	-0.04	-0.17	0.51	-0.31	-0.56	-0.35	-0.3	-0.32	-0.69	0.4		1.0
Short Long Term Debt	-0.17	-0.26	-0.11	0.64	0.18	-0.81	0.19	-0.07	0.14	-0.04	-0.17	0.51	-0.31	-0.56	-0.35	-0.3	-0.32	-0.69	0.4	1.0

Click cells to compare fundamentals

About Kiora Pharmaceuticals Financial Statements

Kiora Pharmaceuticals investors use historical fundamental indicators, such as Kiora Pharmaceuticals' Book Value Per Share, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Kiora Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Book Value Per Share	11.36	11.92
Tangible Book Value Per Share	(5.03)	(5.28)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

F	Ford Motor
GOOG	Alphabet Inc Class C
CRM	Salesforce

Additional Tools for Kiora Stock Analysis

When running Kiora Pharmaceuticals' price analysis, check to measure Kiora Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kiora Pharmaceuticals is operating at the current time. Most of Kiora Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kiora Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kiora Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kiora Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC